<SEC-DOCUMENT>0000935836-26-000399.txt : 20260813
<SEC-HEADER>0000935836-26-000399.hdr.sgml : 20260813
<ACCEPTANCE-DATETIME>20260813142709
ACCESSION NUMBER:		0000935836-26-000399
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260813
DATE AS OF CHANGE:		20260813

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aprea Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781983
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91159
		FILM NUMBER:		261272414

	BUSINESS ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902
		BUSINESS PHONE:		215-948-4119

	MAIL ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LYTTON LAURENCE W
		CENTRAL INDEX KEY:			0001105806
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		467 CENTRAL PARK WEST
		CITY:			NY
		STATE:			NY
		ZIP:			10025
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0000935836-25-000708</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: LYTTON LAURENCE W -->
          <cik>0001105806</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001781983</issuerCik>
        <issuerName>Aprea Therapeutics, Inc.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>03836J201</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>3805 OLD EASTON ROAD</com:street1>
          <com:city>DOYLESTOWN</com:city>
          <com:stateOrCountry>PA</com:stateOrCountry>
          <com:zipCode>18902</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>LYTTON LAURENCE W</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>322220.00</soleVotingPower>
        <sharedVotingPower>68587.00</sharedVotingPower>
        <soleDispositivePower>322220.00</soleDispositivePower>
        <sharedDispositivePower>68587.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>390807.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>3.2</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>The percentage reported herein is calculated based on 12,382,776 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the issuer for the quarter ended March 31, 2026.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Aprea Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>3805 Old Easton Road, Doylestown, PA 18902</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Laurence W. Lytton</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>467 CENTRAL PARK WEST, NEW YORK, NY  10025</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>390,807</amountBeneficiallyOwned>
        <classPercent>3.2%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>322,220</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>68,587</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>322,220</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>68,587</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>LYTTON LAURENCE W</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Laurence W. Lytton</signature>
        <title>Reporting Person</title>
        <date>08/13/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
